Literature DB >> 11870181

Mathematical model to predict individual survival for patients with renal cell carcinoma.

Amnon Zisman1, Allan J Pantuck, Fredrick Dorey, Debby H Chao, Barbara J Gitlitz, Nancy Moldawer, Dana Lazarovici, Jean B deKernion, Robert A Figlin, Arie S Belldegrun.   

Abstract

PURPOSE: To develop a multivariate model and mathematical formula capable of calculating personalized survival for renal cell carcinoma (RCC) patients with clinically available variables. PATIENTS AND METHODS: A total of 477 patients out of 661 undergoing nephrectomy at the University of California Los Angeles between 1989 and 1999 were eligible for evaluation and formed the analyzed cohort for this retrospective study. Time to death was the primary end point assessed. Univariate analysis for 14 to 20 variables was conducted, followed by a multivariate Cox analysis. The variables that provided independent information as to the time of death for metastatic and nonmetastatic patients were coded and incorporated into a function based on the Nadas equation principle.
RESULTS: For nonmetastatic patients, the significant variables in the multivariate analysis were Fuhrman's grade and Eastern Cooperative Oncology Group performance status. For the metastatic patients, Fuhrman's grade, 1997 classification T stage, number of symptoms, nodal involvement, and immunotherapy were independent predictors for survival. These variables, based on the Cox multivariate regression model, were implanted into an exponential Nadas equation. The expected survival predicted by use of the Nadas equations faithfully describes the actual survival based on Kaplan-Meier curves.
CONCLUSION: We have developed mathematical equations for estimating survival after radical nephrectomy for RCC. The resulting formulas are capable of better tailoring survival estimates for a specific patient and are based on widely accepted clinical prognostic variables. On validation with external data, this type of representation can be used as a tool for the determination of personalized prognosis and may be useful for patient education and counseling.

Entities:  

Mesh:

Year:  2002        PMID: 11870181     DOI: 10.1200/JCO.2002.20.5.1368

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  28 in total

1.  Target-specific therapy requires target-specific populations in the treatment of renal cell carcinoma.

Authors:  Robert A Figlin; H Alvin; C L Meinhardt
Journal:  Urologe A       Date:  2004-09       Impact factor: 0.639

2.  Influence of segmentation margin on machine learning-based high-dimensional quantitative CT texture analysis: a reproducibility study on renal clear cell carcinomas.

Authors:  Burak Kocak; Ece Ates; Emine Sebnem Durmaz; Melis Baykara Ulusan; Ozgur Kilickesmez
Journal:  Eur Radiol       Date:  2019-02-12       Impact factor: 5.315

3.  Validation of a Postoperative Nomogram Predicting Recurrence in Patients with Conventional Clear Cell Renal Cell Carcinoma.

Authors:  Byron H Lee; Andrew Feifer; Michael A Feuerstein; Nicole E Benfante; Lei Kou; Changhong Yu; Michael W Kattan; Paul Russo
Journal:  Eur Urol Focus       Date:  2016-07-28

4.  American Confederation of Urology (CAU) experience in minimally invasive partial nephrectomy.

Authors:  Fernando P Secin; Octavio A Castillo; José J Rozanec; Marcelo Featherston; Pablo Holst; José Cocisfran Alves Milfont; Patricio García Marchiñena; Alberto Jurado Navarro; Anamaría Autrán; Agustín R Rovegno; Oscar Rodríguez Faba; Joan Palou; Victor Teixeira Dubeux; Luciano Nuñez Bragayrac; Rene Sotelo; Stenio Zequi; Gustavo Cardoso Guimarães; Mario Álvarez-Maestro; Luis Martínez-Piñeiro; Gustavo Villoldo; Alberto Villaronga; Diego Abreu Clavijo; Ricardo Decia; Rodrigo Frota; Ivar Vidal-Mora; Diana Finkelstein; Juan I Monzó Gardiner; Oscar Schatloff; Andres Hernández-Porrás; Félix Santaella-Torres; Emilio T Quesada; Rodolfo Sánchez-Salas; Hugo Dávila; Humberto Villavicencio Mavric
Journal:  World J Urol       Date:  2016-04-30       Impact factor: 4.226

Review 5.  Prognostic factors in renal cell carcinoma.

Authors:  Alessandro Volpe; Jean Jacques Patard
Journal:  World J Urol       Date:  2010-04-03       Impact factor: 4.226

Review 6.  Recurrence in Localized Renal Cell Carcinoma: a Systematic Review of Contemporary Data.

Authors:  Jacqueline M Speed; Quoc-Dien Trinh; Toni K Choueiri; Maxine Sun
Journal:  Curr Urol Rep       Date:  2017-02       Impact factor: 3.092

7.  Evaluating overall survival and competing risks of death in patients with localized renal cell carcinoma using a comprehensive nomogram.

Authors:  Alexander Kutikov; Brian L Egleston; Yu-Ning Wong; Robert G Uzzo
Journal:  J Clin Oncol       Date:  2009-11-23       Impact factor: 44.544

8.  Metastatic renal cell carcinoma to the thyroid gland 24 years after the primary tumour.

Authors:  Vincenza Di Stasi; Antonio D'Antonio; Alessia Caleo; Luca Valvano
Journal:  BMJ Case Rep       Date:  2013-01-25

Review 9.  The rationale and the role of lymph node dissection in renal cell carcinoma.

Authors:  Umberto Capitanio; Bradley C Leibovich
Journal:  World J Urol       Date:  2016-06-30       Impact factor: 4.226

10.  A pilot study of antiangiogenic therapy with bevacizumab and thalidomide in patients with metastatic renal cell carcinoma.

Authors:  Dina M Elaraj; Donald E White; Seth M Steinberg; Leah Haworth; Steven A Rosenberg; James C Yang
Journal:  J Immunother       Date:  2004 Jul-Aug       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.